The FDA is set to increase its reliance on real-world data in drug and device applications, as announced by Commissioner Marty Makary during a recent address in New York. This shift includes the consideration of large datasets that lack identifiable patient information, marking a significant evolution in the agency’s approach to evaluating the safety and efficacy of medical products.
This move comes in the context of ongoing discussions about the limitations of traditional clinical trial data, which can often be narrow and not fully representative of diverse patient populations. By integrating real-world evidence, the FDA aims to enhance the robustness of its decision-making process, ultimately leading to more timely access to innovative therapies for patients.
The implications for pharma B2B professionals are profound. Regulatory, QA/QC, CMC, and sourcing teams must now prepare for a landscape where real-world evidence plays a critical role in product development and approval strategies. Additionally, the call for reform in early-phase trials suggests that companies may need to adapt their methodologies to align with the FDA’s evolving expectations, potentially reshaping the entire drug development pipeline.
Use the database as your supply chain compass →
